Hims & Hers Health (HIMS) is exhibiting positive momentum, driven by upward revisions in earnings estimates, reflected in its Zacks Rank #2 (Buy). The consensus EPS estimate for the current quarter has increased by 8.07% to $0.17 per share, a 183.33% increase year-over-year, while the full-year estimate has risen by 5.66% to $0.73 per share, representing a 170.37% increase year-over-year; this trend has contributed to an 8.4% gain in the stock price over the past four weeks.
Hims & Hers Health, Inc. (HIMS) exhibits a notably improved earnings outlook, positioning it as an attractive investment candidate according to the provided analysis. The company has received a Zacks Rank #2 (Buy), a significant indicator considering Zacks #1 Ranked stocks have historically generated an average annual return of +25% since 2008. This positive ranking is supported by strong agreement among covering analysts in raising earnings estimates. Specifically, the consensus EPS estimate for the current quarter is $0.17, representing a +183.33% year-over-year increase, and this estimate has risen 8.07% in the last 30 days due to one upward revision and no downward revisions. For the full year, HIMS is expected to earn $0.73 per share, a +170.37% year-over-year surge, with the consensus estimate increasing 5.66% over the past month based on similar revision trends. This growing analyst optimism reflects positively on the company's earnings prospects, aligning with empirical research that shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Consequently, HIMS's stock has gained 8.4% over the past four weeks, reflecting investor confidence driven by these solid estimate revisions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
